Community Bank N.A. Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Community Bank N.A. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,873 shares of the biopharmaceutical company’s stock after selling 225 shares during the period. Community Bank N.A.’s holdings in Gilead Sciences were worth $1,610,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in GILD. Strategic Blueprint LLC raised its holdings in Gilead Sciences by 8.1% during the 3rd quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 328 shares during the last quarter. Proficio Capital Partners LLC bought a new position in Gilead Sciences in the 3rd quarter worth $207,000. Koshinski Asset Management Inc. raised its holdings in Gilead Sciences by 5.1% in the 3rd quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 145 shares in the last quarter. DeDora Capital Inc. raised its holdings in Gilead Sciences by 13.1% in the 3rd quarter. DeDora Capital Inc. now owns 10,114 shares of the biopharmaceutical company’s stock worth $758,000 after purchasing an additional 1,170 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC raised its holdings in Gilead Sciences by 11.9% in the 3rd quarter. Measured Wealth Private Client Group LLC now owns 13,931 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 1,478 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $1.51 during trading hours on Thursday, reaching $65.57. The company had a trading volume of 6,591,565 shares, compared to its average volume of 7,303,500. The business has a fifty day moving average price of $71.56 and a 200-day moving average price of $76.39. Gilead Sciences, Inc. has a one year low of $65.26 and a one year high of $87.86. The firm has a market cap of $81.64 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the prior year, the firm earned $1.67 earnings per share. The business’s revenue was down 3.7% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post 5.24 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.70%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on GILD shares. StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. Royal Bank of Canada reduced their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Barclays reduced their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.57.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.